Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Why China Everbright stock is back in focus
China Everbright (SEHK:165) has drawn fresh attention after the company guided for a 70% to 80% drop in first half 2026 profit attributable to shareholders compared with HK$399 million a year earlier.
See our latest analysis for China Everbright.
The earnings warning comes after a period where China Everbright's share price has been under pressure, with the year to date share price return down 35.95% and the 1 year total shareholder return down 33.17%, even though the 3 year total shareholder return is up 37.26%. Recent weeks have seen some short term interest return, with a 30 day share price return of 10.64% and a 7 day share price return of 4.2% lifting the stock to HK$6.085, which suggests sentiment has improved slightly despite the guidance and recent issuance of RMB 3b in medium term notes.
If you are weighing this shift in sentiment and want to see what else the market is pricing in, now is a good time to broaden your search and check out 106 top founder-led companies
China Everbright's sharp profit warning, alongside a recent share price rebound, sets up a simple fork in the road. Has the key recovery already played out, or is the recent move just the start of the upside debate?
Preferred Price-to-Sales Multiple of 7.8x: Is it justified for China Everbright?
China Everbright trades on a P/S of 7.8x, while the Hong Kong Capital Markets industry sits at 3.6x and direct peers average 6.7x. That points to a richer valuation relative to comparable stocks at the current HK$6.085 share price.
The P/S ratio compares a company's market value to its revenue. For a diversified financial group like China Everbright, which earns fees and investment income across fund management and principal investment activities, investors often look at P/S when earnings are volatile or negative. It provides a way to compare what the market is paying for each dollar of reported revenue across different platforms and strategies.
Here, the higher P/S multiple suggests the market is assigning a premium to China Everbright's HK$1,321.498m of revenue despite the company reporting a loss of HK$2,007.723m and having 100% of its liabilities funded through higher risk external borrowing rather than customer deposits. Given the company's unprofitable status and the statement that losses have increased at 30.1% per year over the past 5 years, that premium raises questions about whether investors are pricing in improvements that are not yet reflected in the available data.
Compared with the broader Hong Kong Capital Markets industry P/S of 3.6x, China Everbright's 7.8x multiple is more than double the sector level. It is also above the 6.7x peer average, which reinforces the idea that the stock is priced at a premium to both its industry and closer comparables on this revenue measure.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Preferred multiple of Price-to-Sales of 7.8x (OVERVALUED)
However, China Everbright's recent profit warning and reliance on higher risk external borrowing could quickly challenge any optimism if funding conditions or deal activity move against it.
Find out about the key risks to this China Everbright narrative.
Next Steps
If this China Everbright update feels mixed to you, now is the moment to look through the details yourself and decide what really matters. To help frame the downside, start by reviewing the 1 important warning sign .
Looking for more investment ideas beyond China Everbright?
If China Everbright has sharpened your focus on valuation and risk, you can use this momentum to line up a few more potential stocks to review next.
-
Target resilient potential by scanning companies that appear attractively valued relative to their fundamentals with the 252 high quality undervalued stocks .
-
Strengthen your income watchlist by checking out stocks that feature higher yields and sturdy payout profiles through the 440 dividend fortresses .
-
Prioritize capital protection by reviewing companies that show lower overall risk profiles via the 298 resilient stocks with low risk scores .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 0165.HK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
